# Safety and Efficacy of Intravenous Administration of SHED-CM for ALS

> **NCT06889857** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Hitonowa Medical** · enrollment: 10 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **BIOLOGICAL:** The study drug is SHED-CM manufactured by U-Factor

## Key facts

- **NCT ID:** NCT06889857
- **Lead sponsor:** Hitonowa Medical
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-05
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06889857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06889857, "Safety and Efficacy of Intravenous Administration of SHED-CM for ALS". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06889857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*